OSTAR Launches First Cellular TeleHealth Blood Pressure System for CHF

Published on:

 

VANCOUVER, Wash., Jan. 30, 2015-- OSTAR Healthcare Technology, a Washington StateBased TeleHealth Solutions company, announced the North American launch of yet another first in theirCellular TeleHealth Blood Pressure Monitoring System. This advanced chronic disease remote monitoring system, is committed to aiding in reduction of 30 day readmission rates for heart patients, in particular Congestive Heart Failure (CHF). According to Doug Hemenway, CEO, "This North American launch of OSTAR CELLULAR P201™ brings forth another market first, a unique cell enabled health device with a combined data gateway approach. With ability to use OSTAR health insurance card reader. The OSTAR P201, delivers more than real time remote blood pressure monitoring, it also provides data input gateway ability, accepting and transmitting other patient centered data from Glucometers, Weight Scales and all other vital signs devices. All OSTAR products reinforce OSTAR's commitment to advanced remote monitoring, reducing 30 Day Readmission Rates, in line with (CMS) edicts, improving patient outcomes, avoiding unnecessary costs, as required by Accountable Care Act (PPACA)."

Photo - http://photos.prnewswire.com/prnh/20150129/172275 
Photo - http://photos.prnewswire.com/prnh/20150129/172276

OSTAR Healthcare Technology – P201™ Remote TeleHealth Blood Pressure Gateway System,provides a cellular device with combined mHealth Personal Dashboard app, seamlessly transmitting relevant data to Population Health Management Systems, Wellness Platforms, EMR's and HIE's, anywhere in the world. OSTAR Healthcare Technology – P201 Remote Cellular TeleHealth Blood Pressure Gateway System is the first Cellular P Series to be released. "Given the current transformation of healthcare in the United States, this simple cellular enabled, insurance card enabled, remote TeleHealth solution, has the potential to positively impact advanced chronic disease management outcomes. Furthermore, the concept will impact shared saving plans in Accountable Care Organizations, while also positively impacting health insurance indicators such as HEDIS, with regards to Medicare Advantage Star Rating programs," as stated by Dr Paul A. Markham, Chief Operating Officer OSTAR Healthcare Technology. The result is reduced cost to healthcare systems and the American healthcare consumer.

About OSTAR

Based in Vancouver, OSTAR Healthcare Technology's unique suite of Next Generation Patient Monitoring solutions brings forth superiority over conventional products specification, quality and lower price; we challenge entire global hospitals blood pressure and oximeter measuring instruments. OSTAR services the academic teaching, acute, ambulatory and home care marketplace.

CONTACT INFORMATION:                                                             
Dr. Paul A. Markham 
OSTAR Healthcare Technology
Email 
www.ostar.us 
Toll free: 844-88-OSTAR   Fax: 360-883-6086

 

SOURCE OSTAR Healthcare Technology

Related Content

Amazon One Medical sued after patient prescribed inhaler dies in ER
DEA, HHS extend telehealth controlled substance prescription rule
Association of 300 telehealth groups urges Congress to extend COVID-era rules
Eli Lilly releases cheaper, single-use vials of weight loss drug
Walmart sells virtual care business to Fabric
AMA will aggressively support permanent telemedicine reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.